A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.

Katherine BunclarkMichael NewnhamYi-Da ChiuAlessandro RuggieroSofia S VillarJohn E CannonGerry CoghlanPaul A CorrisLuke HowardDavid JenkinsMartin JohnsonDavid G KielyChoo NgNicholas ScreatonKaren ShearesDolores TaboadaSteven TsuiStephen John WortJoanna Pepke-ZabaMark R Toshner

Published in: Journal of thrombosis and haemostasis : JTH (2019)

Post-PEA functional and hemodynamic outcomes appear unaffected by anticoagulant choice. Bleeding events were similar, but recurrent VTE rates significantly higher in those receiving DOACs. Our study provides a strong rationale for prospective registry data and/or studies to evaluate the safety of DOACs in CTEPH.

Keyphrases

venous thromboembolism
atrial fibrillation
direct oral anticoagulants
pulmonary hypertension
electronic health record
pulmonary artery
clinical trial
pulmonary arterial hypertension
type diabetes
decision making
drug induced